Back to top

Omeros (OMER) Surges: Stock Moves 10.2% Higher

Read MoreHide Full Article

Omeros Corporation (OMER - Free Report) was a big mover last session, as the company saw its shares rise more than 10% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, trading within a volatile range of $13.96–$26.69 in the past one-month time frame, showed a sharp increase yesterday.

The move came after the company announced positive data from the ongoing phase 2 clinical study of experimental drug OMS721 for the treatment of IgA nephropathy.

The company has seen no changes when it comes to estimate revision over the past month, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.

Omeros currently has a Zacks Rank #4 (Sell) while its Earnings ESP is 0.00%.

Investors interested in the Medical - Products industry may consider a better-ranked stock like Surmodics, Inc. (SRDX - Free Report) , which carries a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is OMER going up? Or down? Predict to see what others think:Up or Down

Best Electric Car Stock? You'll Never Guess It.

Zacks Research has released a report that may shock many investors. One stock stands out as the best way to invest in the surge to electric cars. And it's not the one you may think!

Much like petroleum 150 years ago, lithium battery power is set to shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge. With battery prices plummeting and charging stations set to multiply, revenues that were already at $31 billion in 2016 are expected to blast to over $67 billion by the end of 2022.

See Zacks Best EV Stock Free >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Surmodics, Inc. (SRDX) - free report >>

Omeros Corporation (OMER) - free report >>

More from Zacks Tale of the Tape

You May Like

Published in